The Elijah E. Cummings Lower Drug Costs Now Act: How It Would Work, How It Would Affect Prices, and What the Challenges Are April 9, 2020 | Issue Briefs Featured Will Medicare Prescription Drug Reform Legislation Make Insulin More Affordable?April 2, 2020 | Journal Article Pharmacy Benefit Managers: Practices, Controversies, and What Lies AheadMarch 26, 2019 | Issue Briefs Perverse Incentives: Why Brand-Name Drugs Can Cost Less Than Generics for Medicare BeneficiariesJuly 1, 2019 | Journal Article Reducing Wasteful Spending in Employers’ Pharmacy Benefit PlansAugust 30, 2019 | Issue Briefs Prescription drugs accounted for 17 percent of total U.S. health care spending — or about $457 billion — in 2015. And that share is expected to rise over the next decade as drug costs outpace those of all other health care services. Policymakers need unbiased information and insight into what drives pharmaceutical prices and spending so they can develop feasible, effective policy solutions. Leave this field blank Our Experts Lovisa GustafssonVice President, Controlling Health Care Costs Media Mention read on: CNBCJanuary 14, 2019 Here's why many prescription drugs in the US cost so much—and it's not innovation or improvement FDA Actions on Drug Pricing A Timeline Explore Timeline The Latest in Prescription Drugs Narrow by: Author Anderson, ChloeAnderson, GerardAnderson, Kelly E.Baumgartner, Jesse C.Beutel, SophieBishop, ShawnBlumenthal, DavidBrooks-LaSure, ChiquitaCall, AdrienneColeman, AkeiisaCollins, Sara R.Conti, RenaCorr, BillDavis, KarenDoty, Michelle M.Duong, SophiaDusetzina, Stacie B.Ex, PatriciaFowler, ElizabethFrank, Richard G.Fry, CarrieGabel, Jon R.Ginsburg, Paul B.Glied, Sherry A.Green, Matthew Gunja, Munira Z.Gustafsson, LovisaGuyer, JocelynHorvath, JaneJha, AshishJost, Timothy S.Kang, So YeonKenyatta, KahaariKeohane, Laura M.Kesselheim, Aaron S.LaRosa, JoshLieberman, Steven M.Llamas, AlyssaMann, CindyMartin, KristiMcDonald, RuthMorgan, StevenMoulds, DonaldNuzum, RachelOran, RebeccaOsborn, RobinPanteli, DimitraPapanicolas, IreneParasrampuria, SonalPaxton, IsabelRamsay, ChristinaRiley, TrishRobinson, James C.Rodwin, Marc A.Rother, JohnSarnak, Dana O.Schneider, Eric C.Schoen, CathySeeley, ElizabethSeervai, ShanoorSen, Aditi P.Shah, ArnavSharp, JeremySquires, DavidStromberg, SamVela, LaurenWaxman, HenryWhitmore, HeidiWillink, AmberWoskie, Liana R.Wynne, BillyZhu, Benjamin Date Last 7 daysLast 30 daysLast 6 monthsPast yearOver a year agoOver 2 years agoOver 3 years agoOver 4 years agoOver 5 years ago Type Fund ReportsTo The PointIssue BriefsExplainerInfographicJournal ArticlePodcast View By: Card View Card View List View Apply Leave this field blank To the Point Health Care in the 2020 Presidential Election: Prescription Drugs October 7, 2020 By Lovisa Gustafsson, Elizabeth Fowler Publication Getting to Lower Prescription Drug Prices: The Key Drivers of Costs and What Policymakers Can Do to Address Them October 1, 2020 By Henry Waxman, Bill Corr, Jeremy Sharp, Ruth McDonald, Kahaari Kenyatta Publication Not So Sweet: Insulin Affordability over Time September 25, 2020 By Sherry A. Glied, Benjamin Zhu Publication Catastrophic Coverage in the Medicare Part D Drug Benefit: Which Beneficiaries Need It and How Much Are They Spending? September 17, 2020 By Aditi P. Sen, Sonal Parasrampuria, Kelly E. Anderson, Gerard Anderson To the Point The Cost of Speed: FDA Regulatory Flexibilities During the Coronavirus Pandemic August 20, 2020 By Jeremy Sharp, Kahaari Kenyatta To the Point Drug Pricing and Pandemic Preparedness in the 2022 FDA User Fee Reauthorization Process July 23, 2020 By Jeremy Sharp, Kahaari Kenyatta To the Point COVID-19 Highlights Problems with Our Generic Supply Chain May 7, 2020 By Lovisa Gustafsson Publication FDA Action on Drug Pricing: A Timeline April 24, 2020 Publication The Elijah E. Cummings Lower Drug Costs Now Act: How It Would Work, How It Would Affect Prices, and What the Challenges Are April 9, 2020 By Paul B. Ginsburg, Steven M. Lieberman Publication Will Medicare Prescription Drug Reform Legislation Make Insulin More Affordable? April 2, 2020 By Stacie B. Dusetzina, Laura M. Keohane To the Point Comparative Effectiveness Research, 10 Years After the ACA: Where Do We Go from Here? March 12, 2020 By Jesse C. Baumgartner, Lovisa Gustafsson To the Point The Forecast for Legislative and Regulatory Activity on Health Care in 2020 February 6, 2020 By Billy Wynne, Alyssa Llamas, Josh LaRosa Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next › Last page Last »
